The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moris, A.
Right arrow Articles by Rammensee, H.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moris, A.
Right arrow Articles by Rammensee, H.-G.
The Journal of Immunology, 2001, 166: 4818-4821.
Copyright © 2001 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: Characterization of Allorestricted and Peptide-Selective Alloreactive T Cells Using HLA-Tetramer Selection1

Arnaud Moris2,*, Volker Teichgräber*, Laurent Gauthier{dagger}, Hans-Jörg Bühring{ddagger} and Hans-Georg Rammensee3,*

* Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany; {dagger} Immunotech, Beckmann-Coulter, Marseille, France; and {ddagger} Medical Clinic, Department II, Tübingen, Germany


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
The vast majority of alloreactive T cells recognize foreign MHC molecules in a peptide-dependent manner. A subpopulation of these peptide-dependent alloreactive T cells is peptide-specific and contains T cells that are of interest for tumor immunotherapy. Allorestricted T cells (i.e., peptide-specific and alloreactive) specific for tumor-associated Ags can be raised in vitro. However, it is technically difficult to distinguish between peptide-specific and peptide-nonspecific alloreactive T cells by functional assays in vitro. Here we show for the first time that allorestricted T cells specifically bind HLA-peptide tetrameric complexes, as nominal Ag-specific T cells would do. In consequence, fluorescent HLA-peptide tetrameric complexes can be used for sorting and cloning of allorestricted CTLs specific for a peptide of interest. We also show by the mean of HLA-peptide tetramers the existence of peptide-selective alloreactive T cells that recognize a conformation on the foreign-MHC brought about by some but not all peptides bound.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
Allograft rejection and graft-vs-host disease (GVHD)4 are the clinical manifestations of T cell reactivity to foreign MHC molecules (1). The molecular basis of allorecognition has been extensively studied (2, 3). The nature of the determinants involved in the alloreactive T cell recognition appears to be very diverse (2). The targets of alloreactivity, the MHC class I molecules, bind 8- to 10-aa peptides from intracellular sources and display them at the cell surface. CTL clones that seem to recognize allogeneic molecules in a peptide-independent fashion have been reported (2, 4, 5). Several studies have indicated the existence of peptide-dependent but not peptide-specific CTLs (2, 6). This fraction of alloreactive T cells might be sensitive to the conformation of the MHC that is adapted when particular, but unrelated, peptides are bound (3). The existence of peptide-specific alloreactive T cells has been clearly demonstrated (2, 7, 8, 9, 10). These allorestricted CTLs can recognize specific peptide-MHC complexes just like nominal Ag-specific T cells do (11, 12, 13). By using peptide libraries, our group has recently shown that the mouse as well as the human allorestricted T cell repertoire is broad and diverse (11, 13).

Many tumors overexpress normal proteins thereby modifying the set of self-peptides associated with MHC class I molecules. This phenomenon allows triggering of tumor-specific CTLs. However, CTLs undergo negative selection and peripheral tolerance mechanisms that diminish the number or eliminate self-peptide-specific CTLs. This is an obvious limitation to generate in vitro tumor-specific cytotoxic T cells to be used in adoptive immunotherapy. The existence of the allorestricted repertoire raises the possibility of generating CTLs reactive against synthetic self-peptides bound to nonself-MHC molecules, because tolerance to self-Ags is self-MHC restricted (14). Thus, it should be possible to produce in vitro CTL against self-Ags that are expressed in tumor cells for adoptive immunotherapy (14, 15). Indeed, it has been shown recently that allorestricted CTLs specific for mdm-2 wild-type peptide can be a successful reagent for immunotherapy in mice (12). These CTLs can engraft and retain specificity in the host without causing GVHD (16). We and others (15) evaluate the possibility to isolate allorestricted CTLs that originate from HLA-A*02-negative donors and recognize specifically HLA-A2-peptide complexes. However, the in vitro generation of such allorestricted T cells remains problematic because of the difficulty to separate between the large pool of alloreactive (i.e., recognizing foreign MHC) and the small fraction of allorestricted (i.e., restricted for a particular peptide on foreign MHC) CTL activities. Here, we investigated whether allorestricted T cells can bind HLA-tetrameric complexes specifically, as Ag-specific T cells would do, and whether HLA tetramers can be used for sorting and cloning of allorestricted CTLs specific against a peptide of interest.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Cells

The human EBV-transformed lymphoblastoid B cell lines (LCL) 721 (HLA-A*0201, -A*01, -B*05, -Cwl) (17), the TAP-deficient cell line T2 (HLA-A*0201low, -B*5low, -Cwllow) (18), the {beta}2-microglobulin-deficient Burkitt’s Lymphoma Daudi (HLA-) (19), and the breast carcinoma cell line KLHE (HLA-A*02-) (kindly provided by Dr. B. Gückel, Tübingen, Germany) were used in 51Cr release assays or for T cell stimulation.

Generation of CTLs

PBL from healthy donors registered in the Blood Bank (Tübingen, Germany) were isolated from buffy coats by Ficoll-Hypaque density gradient centrifugation using Lymphoprep (Nycomed, Oslo, Norway). PBLs (107) were stimulated with (106) irradiated T2 cells (200 Gy) pulsed with peptide. Peptide loading was performed for 4 h at room temperature with 10 µM peptide in serum-free medium (20). After 5 days of culture, IL-2 (20 U/ml) was added to the culture medium (Proleukin; Chiron, Ratingen, Germany). After 10 days of culture, the bulk cultures were analyzed by FACS using tetramers and restimulated with (106) irradiated T2 cells pulsed with peptide in IL-2-containing medium. After sorting, the cells were seeded at 1 cell/well in 96-well plates (Costar, Bodenheim, Germany) with 4 x 104 irradiated syngeneic PBL (30 Gy) and 2 x 104 irradiated T2 cells pulsed with peptide. The cultures were restimulated weekly in the same fashion and tested in 51Cr release assays against T2 and 721 target cells. Wells containing CTLs preferentially recognizing peptide-loaded targets or binding tetramers were expanded. All T cell cultures were performed in IMDM (Life Technologies, Eggenstein, Germany), 10% human serum (Pel Freez; Mast-diagnostica, Hamburg, Germany), 20 U/ml IL-2 (Proleukin or Lymphocult; Biotest, Dreieich, Germany), 2 mM glutamine (BioWhittaker, Verviers, Belgium), and 50 U/ml penicillin/50 µg/ml streptomycin solution (BioWhittaker).

HLA-peptide tetrameric complexes and flow cytometry

HLA-peptide tetrameric complexes were produced as previously described (21). In brief, the HLA heavy chain was modified by deletion of the transmembrane domain and COOH-terminal addition of a sequence containing the BirA enzymatic biotinylation site (21). The HLA-A2 heavy chain and {beta}2-microglobulin were produced using a prokaryotic expression system (pET/HLA-A*0201, pET/{beta}2m plasmids, and bacteria kindly provided by Dr. Vincenzo Cerundolo), purified and refolded in vitro by limiting dilution with the HLA-A*201 binding peptides. The HLA-A*201 binding peptide used were Influenza matrix protein (MP)58–66 GILGFVFTL (22), carcinoembryonic Ag (CEA)694–702 GVLVGVALI (23), and tyrosinase A (TyrA)369–377 YMDGTMSQV (24). The refolded complexes were purified by gel filtration (Superdex 75; Pharmacia, Uppsala, Sweden) using fast protein liquid chromatography, biotinylated by BirA (Avidity, Denver, CO) in the presence of biotin (Sigma, Deisenhofen, Germany), ATP (Sigma), and Mg2+ (Sigma). The biotinylated product was separated from free biotin by gel filtration and ion exchange (MonoQ; Pharmacia) using fast protein liquid chromatography. Tetramers were assembled by mixing biotinylated protein complexes with streptavidin-PE (Molecular Probes, Eugene, OR) at a molecular ratio of 4:0.8.

A total of 4 x 106 cells from the in vitro allostimulations or 2 x 105 CTL clones were incubated on ice or 37°C with 10 µg/ml tetrameric complexes. After 15 min of incubation, cells were washed extensively with PBS containing 1% FCS. CD8 Ab (Caltag Laboratories, Burlingame, CA) and CD4 Ab (Immunotech, Marseilles, France) were added, and the samples were incubated on ice for further 15 min. After extensive washing, samples were fixed with PBS containing 2% formaldehyde. Triple-color analysis was performed with tetramer-PE, CD8-Tricolor, and CD4-FITC using a FACSCalibur (Becton Dickinson, Heidelberg, Germany) and CellQuest software (Becton Dickinson). Sorting was performed without fixation and using a FACSVantage (Becton Dickinson).

Cytotoxicity assay

Targets were labeled with 1.85 MBq of Na251CrO4 for 1 h at 37°C, with or without preincubation with peptide (50 µM) for 1–2 h at room temperature in serum-free medium. Labeled targets were incubated for 4 h with the CTLs in RPMI 1640 (Life Technology), 10% FCS (Sigma), 2 mM glutamine (BioWhittaker), and 50 U/ml penicillin/50 µg/ml streptomycin solution (BioWhittaker). Subsequently, 50 µl of the supernatant was harvested. Percent specific lysis was calculated as (cpm experimental counts - cpm media control)/(cpm detergent - cpm media control) x 100%. Medium controls were between 10 and 15% of detergent samples.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
PBLs from an HLA-A*02-negative healthy donor (HLA-A*01/*24, -B*08, -Cw7) were stimulated in vitro with the TAP-deficient cell line T2 loaded with the MP58–66 peptide as a model Ag (22). The low level of peptides in this TAP-mutant T2 cell line causes most MHC class I molecules to remain empty or to associate with low-affinity peptides (25). By the external addition of peptides, empty molecules can be stabilized and low-affinity peptides replaced (20), leading to stimulation of the PBLs with a high copy number of a single peptide-MHC complex.

To separate between alloreactive CTL and allorestricted CTL activities, we constructed HLA-A*0201-peptide tetrameric complexes based on the MP58–66 peptide. HLA-tetrameric complexes have been developed by Altman et al. (21) to study peptide-specific CD8+ T cells. They have been used to follow the fate of the immune response after viral or bacterial infections (26, 27). They allowed characterization of cell surface Ags expressed by autoantigen-specific T cells in autoimmune disorders and in tumor patients (26, 28). HLA-peptide tetrameric complexes bind to Ag-specific CTLs with high specificity and show no cross-reactivity on CTLs specific for an irrelevant peptide. Tetramer binding is known to correlate with both peptide-specific cytolytic functions and cytokine secretions (26). Furthermore, even down to very low frequencies of Ag-specific T cells, HLA-peptide tetramers allow direct isolation of tetramer-positive cells by FACS (29).

By analysing the bulk alloreactive culture with an HLA-A*02-MP tetramer that stained specifically a MP58–66-specific CTL clone (Fig. 1GoA), we observed a very low but significant frequency of allorestricted CTLs specific for the MP58–66 peptide (Fig. 1GoD). This specific staining was seen only among the T cell blast population (Fig. 1GoD). No staining was observed in the T cell population that was gated for the unstimulated small and round T cells (Fig. 1GoC) and in the fresh PBLs of the same donor (data not shown, see also 29). Furthermore, using an irrelevant HLA-A*02-peptide tetrameric complex folded with the CEA694–702 peptide, no staining was detectable in both the unstimulated and the blast T cell population (data not shown and Fig. 1GoB, respectively). A striking observation in this experiment is that the vast majority of alloreactive T cells can not bind the HLA-peptide tetramers (Fig. 1Go), although such bulk cultures kill T2 cells, as we know from other experiments (data not shown). Among mouse and human alloreactive CTLs, a dominance of peptide-dependent recognition has been described (30, 31). The determinant recognized by the majority of those alloreactive CTLs that do not bind the HLA-peptide tetrameric complexes in our culture could therefore be dependent on TAP-independent peptides presented by the HLA-A*02 molecule on T2 cells. An alternative explanation would be that these alloreactive CTLs are of low affinity and need a high density of MHC-peptide complexes to be activated in vitro (32) and that we are not providing enough HLA-peptide complexes to stain these low-affinity T cells. In any case, this experiment clearly shows that the bulk of alloreactive T cells directed against HLA-A2 is not stained by specific HLA-A2-peptide tetramers.



View larger version (50K):
[in this window]
[in a new window]
  		FIGURE 1. HLA-A*02 tetramer staining of allorestricted CTLs. HLA-A*0201-MP58–66-specific CTL clone was stained with HLA-A*02-MP tetramer (TA2-MP) (A) and CD8 Ab. The alloreactive bulk cultures were stained with HLA-A*02-MP tetramer (TA2-MP) (C and D) or with HLA-A*02-CEA694–702 tetramer (TA2-CEA) (B) and CD8 Ab. Percentage of positive cells is given in each quadrant. The cells from the alloreactive in vitro bulk cultures were gated on size and granularity: small and round (nonactivated) cells and blasts. C shows the staining of the nonactivated cells, and D shows the staining of the activated cells. To discriminate between activated and nonactivated cells was necessary to detect a specific tetramer staining. B shows the staining of the activated cells but with an irrelevant HLA-A*02-CEA tetramer. In B, C, and D, cells that were unspecifically stained by the CD4 Ab were gated out to reduce background.

 
We further examined the peptide specificity of the allorestricted CTLs by sorting the tetramer-positive cells using FACS. Tetramer-sorted cells were plated at 1 cell/well and expanded in vitro using T2 cells loaded with peptide and autologous feeder cells in IL-2-containing medium. The ability of the CTL clones to lyse peptide-pulsed target cells was then assessed (Fig. 2Go). The CD8+ HLA-A*02-MP tetramer+ clones were able to lyse peptide pulsed HLA-A*02+ targets. In contrast, no significant activity was observed on T2 pulsed with an irrelevant peptide (Fig. 2Go). These data confirmed that the tetramer-binding cells in Fig. 1GoC were allorestricted CTLs specific for the MP58–66 peptide.



View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 2. Cytotoxic activity of HLA-A2-MP-sorted alloreactive CTL clones. The nine different clones were tested in a chromium release assay against the HLA-A*0201-positive LCL 721 pulsed with MP58–66 peptide (•) or a control peptide from the RNA-helicase p72 YLLPAIVHI ({circ}).

 
In a second experiment, PBLs from the same HLA-A*02-negative donor were stimulated in vitro with T2 cells as described before. As observed previously, CD8+ HLA-A*02-MP tetramer+ cells were detected after tetramer staining of the bulk culture (data not shown). Peptide specificity of these putative allorestricted CTLs was then assessed again by sorting the tetramer-positive cells using FACS and performing a chromium release assay on peptide-pulsed target cells, as described before (Fig. 3Go). A detailed analysis of one of these CTL clones, BC19-3, is described in Figs. 3Go and -4. In contrast to what we observed previously, HLA-A*02+ peptide-pulsed T2 cells were lysed as well as the unpulsed cells (Fig. 3Go). To exclude that the CTL clones were exhibiting an NK cell-like activity, we performed a killer assay using the NK-sensitive HLA-deficient cell line Daudi and an HLA-A*02-negative target KLHE (Fig. 3GoB). None of the cell lines were recognized by the clones (Fig. 3Go), showing clearly that the lysis was MHC specific and correlates with the expression of HLA-A*02 on the target cells. Thus, these CTL clones are either peptide independent or dependent on TAP-independent peptides on T2. It is not obvious why the alloreactive T cells in this experiment are of different specificity than those in the first experiment (Fig. 1Go), where the majority of tetramer-sorted T cells was peptide specific. One explanation could be that the T cell repertoire of the donor has changed in the meantime, e.g., due to an immune response against an environmental Ag. Another explanation might be a subtle change in MHC expression or peptide loading in T2 cells between the two experiments. In contrast, it is likely that these CTL clones were not specific for a particular TAP-independent peptide on T2 because the wild-type LCL 721 was equally lysed irrespectively of the peptide pulsed (Fig. 3GoB).



View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 3. Cytotoxic activity of the HLA-A2-MP-sorted alloreactive CTL clone BC19-3. A, Targets: TAP-deficient T2 cell line unloaded ({circ}), loaded with MP58–66 (•), CEA694–702 ({blacktriangleup}) or TyrA369–377 ({triangleup}). B, Targets: LCL 721 loaded with MP58–66 (•) or MelanA27–35 AAGIGILTV ({blacklozenge}), unloaded {beta}2-microglobulin-deficient Daudi cells ({square}) and the HLA-A*02-negative breast carcinoma cell line KLHE ({triangleup}).

 
We examined whether the CTL clone described in Fig. 3Go would bind different MHC-peptide complexes using HLA-peptide tetrameric complexes folded with several peptides. As expected, the CTL clone could be stained by the HLA-A*02-MP tetramer that was used for the FACS sorting. However, this clone could also bind the HLA-peptide tetrameric complex folded with the CEA694–702 peptide. In contrast, it could not bind the HLA-peptide tetrameric complex folded with the TyrA369–377 peptide (Fig. 4Go). These particular HLA-peptide tetrameric combinations were used because for each of them a positive control was available consisting either of HLA-A*02-transgenic mouse CTLs or human CTL clones specific for the HLA-A*02-CEA (data not shown) or the HLA-A*02-TyrA tetramers, respectively (data not shown and V. Teichgräber, A. Moris, M. Müller, B. Schittek, C. Garbe, and H.-G. Rammensee, manuscript in preparation). This alloreactive CTL clone is therefore peptide selective but not peptide specific (Fig. 4Go). It might be sensitive to the conformation of the HLA molecule that is adapted when particular, but unrelated, peptides are bound (2, 3). One or more peptides of this sort seem to be present at the surface of T2 and 721 as they are both recognized in a killer assay irrespectively of the peptide pulsed (Fig. 3Go). Our group speculated on the existence of such alloreactive T cells in a previous study where the recognition of HPLC-fractionated Kb-extracted peptides by Kb-specific CTLs was analyzed (2). In that study, a unique alloreactive CTL line that recognized multiple HPLC fractions was described. Different groups obtained analogous results, which suggested that some clones may be peptide dependent but not peptide specific inasmuch as a variety of different peptides could promote their recognition of target cells (2, 33, 34). Thus, the present study shows for the first time directly that such alloreactive peptide-selective CTLs exist.



View larger version (15K):
[in this window]
[in a new window]
  		FIGURE 4. HLA tetramer staining of the alloreactive CTL clone BC19-3. Double staining was performed using the HLA-A*02 tetramers and CD8 Ab: HLA-A*02-CEA694–702 (TA2-CEA) (left panel), HLA-A*02-MP58–66 (TA2-MP) (middle panel), and HLA-A*02-TyrA369–377 (TA2-TyrA) (right panel).

 
Using HLA-peptide tetrameric complexes, we have described a new approach to generate peptide-specific CTL that could be useful for clinical tumor immunotherapy. Allogeneic bone marrow transplantation as treatment of leukemia patients is often associated with GVHD which is detrimental for the patient, but also graft-vs-leukemia (GVL), which is positively correlated with the prognosis (35, 36). Both activities are attributed to alloreactive donor T cells (36). The transfer of donor allorestricted CTLs specific for a leukemia tumor Ag at the same time as stem cell transplantation could be of particular interest to enhance the GVL without causing GVHD (36, 37). A better understanding of the nature of the determinants recognized by GVL-mediating alloreactive CTLs is of obvious interest to establish new transplantation protocols. Importantly, undetected crossreactivity of tumor-specific allorestricted T cells could induce immunopathology such as GVHD. We have shown that HLA-peptide tetrameric complexes are a powerful tool that allows the characterization of recognition patterns by alloreactive T cells and new insights in the molecular basis of alloreactivity.


   Acknowledgments
 
We thank Drs. R. Obst, C. Gouttefangeas, and S. Pascolo for helpful discussions, Dr. S. Stevanovic for synthetic peptides, Anke Marxer for excellent technical assistance, and the Blood Bank in Tübingen for providing buffy coats.


   Footnotes
 
1 This work was supported by the University of Tübingen, "fortune program" number 406-0-0, and by the European Union grant on "CTLs follow up and vaccination: B104-98-0214." Back

2 Current address: Pasteur Institute, Retrovirus and Gene Transfer, 28 rue du Dr. Roux, F-75724 Paris Cedex 15, France. Back

3 Address correspondence and reprint requests to Dr. Hans-Georg Rammensee, Institute for Cell Biology, Department of Immunology, University of Tübingen, Auf der Morgenstelle 15, D-72076 Tübingen, Germany. Back

4 Abbreviations used in this paper: GVHD, graft-vs-host disease; CEA, carcinoembryonic Ag; LCL, lymphoblastoid B cell line; MP, matrix protein; TyrA, tyrosinase A; GVL, graft-vs-leukemia. Back

Received for publication November 30, 2000. Accepted for publication February 26, 2001.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Klein, J.. 1986. Natural History of the Major Histocompatibility Complex Wiley, New York.
  2. Rotzschke, O., K. Falk, S. Faath, H. G. Rammensee. 1991. On the nature of peptides involved in T cell alloreactivity. J. Exp. Med. 174:1059.[Abstract/Free Full Text]
  3. Sherman, L. A., S. Chattopadhyay. 1993. The molecular basis of allorecognition. Annu. Rev. Immunol. 11:385.[Medline]
  4. Elliott, T. J., H. N. Eisen. 1990. Cytotoxic T lymphocytes recognize a reconstituted class I histocompatibility antigen (HLA-A2) as an allogeneic target molecule. Proc. Natl. Acad. Sci. USA 87:5213.[Abstract/Free Full Text]
  5. Smith, P. A., A. Brunmark, M. R. Jackson, T. A. Potter. 1997. Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL). J. Exp. Med. 185:1023.[Abstract/Free Full Text]
  6. Chattopadhyay, S., M. Theobald, J. Biggs, L. A. Sherman. 1994. Conformational differences in major histocompatibility complex-peptide complexes can result in alloreactivity. J. Exp. Med. 179:213.[Abstract/Free Full Text]
  7. Heath, W. R., M. E. Hurd, F. R. Carbone, L. A. Sherman. 1989. Peptide-dependent recognition of H-2Kb by alloreactive cytotoxic T lymphocytes. Nature 341:749.[Medline]
  8. Udaka, K., T. J. Tsomides, H. N. Eisen. 1992. A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein. Cell 69:989.[Medline]
  9. Alexander-Miller, M. A., K. Burke, U. H. Koszinowski, T. H. Hansen, J. M. Connolly. 1993. Alloreactive cytotoxic T lymphocytes generated in the presence of viral-derived peptides show exquisite peptide and MHC specificity. J. Immunol. 151:1.[Abstract]
  10. Tallquist, M. D., T. J. Yun, L. R. Pease. 1996. A single T cell receptor recognizes structurally distinct MHC/peptide complexes with high specificity. J. Exp. Med. 184:1017.[Abstract/Free Full Text]
  11. Obst, R., C. Munz, S. Stevanovic, H. G. Rammensee. 1998. Allo- and self-restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire. Eur. J. Immunol. 28:2432.[Medline]
  12. Sadovnikova, E., H. J. Stauss. 1996. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 93:13114.[Abstract/Free Full Text]
  13. Munz, C., R. Obst, W. Osen, S. Stevanovic, H. G. Rammensee. 1999. Alloreactivity as a source of high avidity peptide-specific human CTL. J. Immunol. 162:25.[Abstract/Free Full Text]
  14. Rammensee, H. G., M. J. Bevan. 1984. Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature 308:741.[Medline]
  15. Stauss, H. J.. 1999. Immunotherapy with CTLs restricted by nonself MHC. Immunol. Today 20:180.[Medline]
  16. Gao, L., T. H. Yang, S. Tourdot, E. Sadovnikova, R. Hasserjian, H. J. Stauss. 1999. Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease. Blood 94:2999.[Abstract/Free Full Text]
  17. Orr, H. T., R. DeMars. 1983. Mapping of class I DNA sequences within the human major histocompatibility complex. Immunogenetics 18:489.[Medline]
  18. Salter, R. D., D. N. Howell, P. Cresswell. 1985. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21:235.[Medline]
  19. Klein, G., G. Clements, J. Zeuthen, A. Westman. 1976. Somatic cell hybrids between human lymphoma lines. II. Spontaneous and induced patterns of the Epstein-Barr virus (EBV) cycle. Int. J. Cancer 17:715.[Medline]
  20. Cerundolo, V., J. Alexander, K. Anderson, C. Lamb, P. Cresswell, A. McMichael, F. Gotch, A. Townsend. 1990. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 345:449.[Medline]
  21. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.[Abstract/Free Full Text]
  22. Bednarek, M. A., S. Y. Sauma, M. C. Gammon, G. Porter, S. Tamhankar, A. R. Williamson, H. J. Zweerink. 1991. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J. Immunol. 147:4047.[Abstract]
  23. Schirle, M., W. Keilholz, B. Weber, C. Gouttefangeas, T. Dumrese, H. D. Becker, S. Stevanovic, H. G. Rammensee. 2000. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur. J. Immunol. 30:2216.[Medline]
  24. Skipper, J. C., R. C. Hendrickson, P. H. Gulden, V. Brichard, A. Van Pel, Y. Chen, J. Shabanowitz, T. Wolfel, C. L. J. Slingluff, T. Boon, D. F. Hunt, V. H. Engelhard. 1996. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183:527.[Abstract/Free Full Text]
  25. Wei, M. L., P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356:443.[Medline]
  26. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, et al 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103.[Abstract/Free Full Text]
  27. Busch, D. H., I. M. Pilip, S. Vijh, E. G. Pamer. 1998. Coordinate regulation of complex T cell populations responding to bacterial infection. Immunity 8:353.[Medline]
  28. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. L. Chen, D. Lienard, J. C. Cerottini, V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641.[Abstract/Free Full Text]
  29. Dunbar, P. R., G. S. Ogg, J. Chen, N. Rust, P. van der Bruggen, V. Cerundolo. 1998. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr. Biol. 8:413.[Medline]
  30. Crumpacker, D. B., J. Alexander, P. Cresswell, V. H. Engelhard. 1992. Role of endogenous peptides in murine allogenic cytotoxic T cell responses assessed using transfectants of the antigen-processing mutant 174xCEM.T2. J. Immunol. 148:3004.[Abstract]
  31. Man, S., R. D. Salter, V. H. Engelhard. 1992. Role of endogenous peptide in human alloreactive cytotoxic T cell responses. Int. Immunol. 4:367.[Abstract/Free Full Text]
  32. Bevan, M. J.. 1984. High determinant density may explain the phenomenon of alloreactivity. Immunol. Today 5:128.
  33. Guimezanes, A., T. N. Schumacher, H. L. Ploegh, A. M. Schmitt-Verhulst. 1992. A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product. Eur. J. Immunol. 22:1651.[Medline]
  34. Bluestone, J. A., A. Kaliyaperumal, S. Jameson, S. Miller, R. Dick. 1993. Peptide-induced changes in class I heavy chains alter allorecognition. J. Immunol. 151:3943.[Abstract]
  35. Horowitz, M. M., R. P. Gale, P. M. Sondel, J. M. Goldman, J. Kersey, H. J. Kolb, A. A. Rimm, O. Ringden, C. Rozman, B. Speck. 1990. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555.[Abstract/Free Full Text]
  36. Molldrem, J. J., P. P. Lee, C. Wang, K. Felio, H. M. Kantarjian, R. E. Champlin, M. M. Davis. 2000. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6:1018.[Medline]
  37. Smit, W. M., M. Rijnbeek, C. A. van Bergen, W. E. Fibbe, R. Willemze, J. H. Falkenburg. 1998. T cells recognizing leukemic CD34+ progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc. Natl. Acad. Sci. USA 95:10152.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 BloodHome page
I. G. Schuster, D. H. Busch, E. Eppinger, E. Kremmer, S. Milosevic, C. Hennard, C. Kuttler, J. W. Ellwart, B. Frankenberger, E. Nossner, et al.
Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies
Blood, October 15, 2007; 110(8): 2931 - 2939.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Asemissen, U. Keilholz, S. Tenzer, M. Muller, S. Walter, S. Stevanovic, H. Schild, A. Letsch, E. Thiel, H.-G. Rammensee, et al.
Identification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1
Clin. Cancer Res., December 15, 2006; 12(24): 7476 - 7482.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Pittet, A. Gati, F.-A. Le Gal, G. Bioley, P. Guillaume, M. de Smedt, J. Plum, D. E. Speiser, J.-C. Cerottini, P.-Y. Dietrich, et al.
Ex Vivo Characterization of Allo-MHC-Restricted T Cells Specific for a Single MHC-Peptide Complex
J. Immunol., February 15, 2006; 176(4): 2330 - 2336.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Filaci, M. Fravega, M. Setti, P. Traverso, E. Millo, D. Fenoglio, S. Negrini, F. Ferrera, A. Romagnoli, M. Basso, et al.
Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer
Blood, February 15, 2006; 107(4): 1505 - 1512.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. J. Felix, A. Suri, J. J. Walters, S. Horvath, M. L. Gross, and P. M. Allen
I-Ep-Bound Self-Peptides: Identification, Characterization, and Role in Alloreactivity
J. Immunol., January 15, 2006; 176(2): 1062 - 1071.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Mulder, C. Eijsink, M. G. D. Kester, M. E. I. Franke, M. J. Kardol, M. H. M. Heemskerk, C. van Kooten, F. A. Verreck, J. W. Drijfhout, F. Koning, et al.
Impact of Peptides on the Recognition of HLA Class I Molecules by Human HLA Antibodies
J. Immunol., November 1, 2005; 175(9): 5950 - 5957.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. S. Rohrlich, N. Fazilleau, F. Ginhoux, H. Firat, F. Michel, M. Cochet, N. Laham, M. P. Roth, S. Pascolo, F. Nato, et al.
From The Cover: Direct recognition by {alpha}{beta} cytolytic T cells of Hfe, a MHC class Ib molecule without antigen-presenting function
PNAS, September 6, 2005; 102(36): 12855 - 12860.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. M. E. Whitelegg, L. E. M. Oosten, S. Jordan, M. Kester, A. G. S. van Halteren, J. A. Madrigal, E. Goulmy, and L. D. Barber
Investigation of Peptide Involvement in T Cell Allorecognition Using Recombinant HLA Class I Multimers
J. Immunol., August 1, 2005; 175(3): 1706 - 1714.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Mulder, C. Eijsink, M. J. Kardol, M. E. I. Franke-van Dijk, S. H. van der Burg, M. Kester, I. I. N. Doxiadis, and F. H. J. Claas
Identification, Isolation, and Culture of HLA-A2-Specific B Lymphocytes Using MHC Class I Tetramers
J. Immunol., December 15, 2003; 171(12): 6599 - 6603.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Rentzsch, S. Kayser, S. Stumm, I. Watermann, S. Walter, S. Stevanovic, D. Wallwiener, and B. Guckel
Evaluation of Pre-existent Immunity in Patients with Primary Breast Cancer: Molecular and Cellular Assays to Quantify Antigen-Specific T Lymphocytes in Peripheral Blood Mononuclear Cells
Clin. Cancer Res., October 1, 2003; 9(12): 4376 - 4386.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. J. Amrolia, G. Muccioli-Casadei, E. Yvon, H. Huls, U. Sili, E. D. Wieder, C. Bollard, J. Michalek, V. Ghetie, H. E. Heslop, et al.
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses
Blood, September 15, 2003; 102(6): 2292 - 2299.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. J. Amrolia, S. D. Reid, L. Gao, B. Schultheis, G. Dotti, M. K. Brenner, J. V. Melo, J. M. Goldman, and H. J. Stauss
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity
Blood, February 1, 2003; 101(3): 1007 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
F. Lenfant, N. Pizzato, S. Liang, C. Davrinche, P. Le Bouteiller, and A. Horuzsko
Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice
J. Gen. Virol., January 1, 2003; 84(2): 307 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Weinschenk, C. Gouttefangeas, M. Schirle, F. Obermayr, S. Walter, O. Schoor, R. Kurek, W. Loeser, K.-H. Bichler, D. Wernet, et al.
Integrated Functional Genomics Approach for the Design of Patient-individual Antitumor Vaccines
Cancer Res., October 15, 2002; 62(20): 5818 - 5827.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Mutis, E. Blokland, M. Kester, E. Schrama, and E. Goulmy
Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation
Blood, June 28, 2002; 100(2): 547 - 552.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Freese and N. Zavazava
HLA-B7 beta -pleated sheet-derived synthetic peptides are immunodominant T-cell epitopes regulating alloresponses
Blood, May 1, 2002; 99(9): 3286 - 3292.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moris, A.
Right arrow Articles by Rammensee, H.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moris, A.
Right arrow Articles by Rammensee, H.-G.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS